Crohn's disease: open trials in Canada

48 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT06006039
The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.
Research · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Mount Sinai, Toronto
Registry updated 2026-11-04
NCT06226883
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 2 · Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
CaRe Clinic, Alberta · Integrated University Health and Social Services Center of Saguenay-Lac-Saint-Jean, Chicoutimi · Nova Scotia Health Authority, Halifax · Prairie Institute of Liver and Luminal Advanced Research, Lethbridge · London Health Sciences Centre, London · London Digestive Disease Institute, London · Clinique IMD, Montreal · Diex Recherche Québec Inc., Québec · Scarborough Center for Inflammatory Bowel Disease, Scarborough · Mount Sinai Hospital, Toronto · St Joseph'S Health Centre Toronto, Toronto · Toronto Digestive Disease Associates, Inc., Vaughan
Registry updated 2026-11-04
NCT06937099
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Trial Treatment · Phase 3 · Eli Lilly and Company
Gastroenterology and internal medicine research institute, Edmonton · London Digestive Disease Institute, London · London Health Sciences Centre, London · Clinique IMD, Montreal · The Ottawa Hospital - General Campus, Ottawa · (G.I.R.I.) GI Research Institute Foundation, Vancouver · Vancouver General Hospital, Vancouver
Registry updated 2026-11-04
NCT07483073
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Trial Treatment · Phase 2 · Eli Lilly and Company
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park · Prairie Institute of Liver and Luminal Advanced Research Ltd (PILLAR), Lethbridge · London Digestive Disease Institute, London · Tdda Inc., Vaughan
Registry updated 2026-11-04
NCT07483099
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Trial Treatment · Phase 2 · Eli Lilly and Company
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park · Prairie Institute of Liver and Luminal Advanced Research Ltd (PILLAR), Lethbridge · London Digestive Disease Institute, London · Tdda Inc., Vaughan
Registry updated 2026-11-04
NCT05923073
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
IWK Health Centre, Halifax · London Health Sciences Centre · Victoria Hospital, London · Hospital for Sick Children, Toronto
Registry updated 2026-11-03
NCT07196722
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 2/3 · Janssen Research & Development, LLC
Barrie GI Associates, Barrie · Gastroenterology and Internal Medicine Research Institute (GIRI), Edmonton · South Edmonton Gastroenterology Research Clinic, Edmonton · Viable Clinical Research, Kentville · London Digestive Disease Institute, London · CHUM - Centre hospitalier universitaire de Montreal, Montreal · ABP Research Services Corp., Oakville · Toronto Immune and Digestive Health Institute Inc, Toronto · GIRI Gastrointestinal Research Institute, Vancouver
Registry updated 2026-11-03
NCT07499232
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Gastroenterology and Internal Medicine Research Institute (GIRI), Edmonton · Charlton Digestive Disease Centre, Hamilton · London Digestive Disease Institute, London · Clinique IMD, Montreal · Centre Hospitalier de l'Université de Montréal, Montreal · Taunton Surgical Centre, Oshawa · Toronto Immune and Digestive Health Institute Inc, Toronto · GIRI Gastrointestinal Research Institute, Vancouver
Registry updated 2026-11-03
NCT07577843
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
South Edmonton Gastroenterology Research Clinic, Edmonton · Gastroenterology and Internal Medicine Research Institute (GIRI), Edmonton · Nova Scotia Health Victoria General Site, Halifax · Viable Clinical Research, Kentville · London Digestive Disease Institute, London · West Gta Research Inc., Mississauga · CHUM - Centre hospitalier universitaire de Montreal, Montreal · Clinique IMD, Montreal · Toronto Immune and Digestive Health Institute Inc, Toronto · GI Research Institute (G.I.R.I.), Vancouver · Toronto Digestive Disease Associates, Inc., Vaughan
Registry updated 2026-11-03
NCT06233461
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 2 · Takeda
Heritage Medical Research Clinic - University Of Calgary, Calgary · Nova Scotia Health Authority - Queen Elizabeth II Heath Sciences Centre, Halifax · London Health Sciences Centre · Victoria Hospital, London · London Health Sciences Centre, University Hospital, London · London Digestive Disease Institute, London · Centre Hospitalier de l'Université de Montréal, Montreal · The Research Institute of the McGill University Health Center, Montreal · Fraser Clinical Trials, New Westminster · University of Toronto - Mount Sinai Hospital - The Lunenfeld-Tanenbaum Research Institute, Toronto
Registry updated 2026-11-02
NCT06430801
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Barrie GI Associates ( Site 0016), Barrie · Heritage Medical Research Clinic ( Site 0004), Calgary · Gastroenterology and internal medicine research institute ( Site 0009), Edmonton · Private Practice - Dr. Bruce Musgrave ( Site 0014), Kentville · Prairie Institute of Liver and Luminal Advanced Research ( Site 0015), Lethbridge · Centre de recherche du CISSS de Chaudière-Appalaches - Hôpital Hôtel Dieu de Levis ( Site 0011), Lévis · London Health Sciences Centre ( Site 0007), London · University Hospital - London Health Sciences Centre ( Site 0002), London · West GTA Research Inc. ( Site 0020), Mississauga · Montreal General Hospital ( Site 0003), Montreal · Centre Hospitalier de l'Université de Montréal - Gastroenterology ( Site 0013), Montreal · Fraser Clinical Trials Inc ( Site 0001), New Westminster · ABP Research Services Corp. ( Site 0019), Oakville · Diex Recherche Quebec ( Site 0008), Québec · Toronto Immune & Digestive Health Institute ( Site 0005), Toronto · G.I.R.I. GI Research Institute Foundation ( Site 0018), Vancouver · TDDA Inc. ( Site 0006), Vaughan
Registry updated 2026-11-02
NCT07697456
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Trial Treatment · Phase 2 · AbbVie
Diex Recherche Quebec Inc. /ID# 282307, Québec
Registry updated 2026-10-27
NCT05928039
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
Trial Treatment · Phase 4 · University of Calgary
GNRR Digestive Clinics and Research Center Inc., Brampton · Rajbir Rai Medical Corporation, Brantford · University Of Calgary, Calgary · University of Alberta IBD Clinic, Edmonton · Nova Scotia Health Victoria, Halifax · McMaster University, Hamilton · London Digestive Disease Institute, London · London Health Sciences Centre, London · West Gta Research Inc., Mississauga · Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal · Hôpital du Sacré-Cœur de Montréal, Montreal · Research Institute of the McGill University Health Centre (MUHC), Montreal · ABP Research Services Corp., Oakville · Taunton Surgical Center, Oshawa · The Ottawa Hospital Research Institute, Ottawa · Université de Sherbrooke, Sherbrooke · Thunder Bay Regional Health Research Institute, Thunder Bay · TIDHI Clinic, Toronto · Sinai Health System, Toronto · GI Research Institute (G.I.R.I.), Vancouver · West Coast Gastroenterology, Vancouver
Registry updated 2026-10-26
NCT06819891
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Hoffmann-La Roche
Barrie GI Associates, Barrie · GNRR Digestive Clinics and Research Center Inc., Brampton · LDDI Clinical Trials Inc., London · London Health Sciences Centre Uni Campus, London · CIUSSS de l Est de l Ile de Montreal - Hopital Maisonneuve Rosemont, Montreal · Toronto Immune and Digestive Health Institute, North YORK
Registry updated 2026-10-26
NCT06997965
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
Trial Treatment · Phase 4 · Alimentiv Inc.
McMaster University Medical Center, Hamilton · London Digestive Disease Institute, London · The Office of Dr. Jason Reinglas, Scarborough Village · GI Institute Research Foundation, Vancouver
Registry updated 2026-10-26
NCT07184931
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Sanofi
Brampton · Edmonton · Greater Sudbury · Hamilton · London · London · Montreal · Montreal · New Westminster · Oakville · Toronto
Registry updated 2026-10-21
NCT07184944
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Sanofi
Edmonton · Hamilton · London · New Westminster · Toronto
Registry updated 2026-10-21
NCT05995353
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · AbbVie
Alberta Children's Hospital /ID# 255357, Calgary · Edmonton Clinic Health Academy /ID# 255361, Edmonton · London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598, London · BC Children's Hospital /ID# 255359, Vancouver
Registry updated 2026-10-20
NCT06819878
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Hoffmann-La Roche
South Edmonton Gastroenterology, Edmonton · C.I.C. Mauricie, Trois-Rivières · TDDA Specialty Research, Vaughan
Registry updated 2026-10-16
NCT06042387
Genome Analysis Across Populations in Inflammatory Bowel Disease
Research · Mount Sinai Hospital, Canada
Sinai Health System, Toronto
Registry updated 2026-10-09
NCT04844606
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Trial Treatment · Phase 3 · Eli Lilly and Company
London Health Sciences Centre, London · The Hospital for Sick Children, Toronto
Registry updated 2026-10-07
NCT05509777
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Trial Treatment · Phase 3 · Eli Lilly and Company
IWK Health Centre, Halifax · London Health Sciences Centre (LHSC) - Victoria Hospital, London · The Hospital for Sick Children, Toronto · Children's & Women's Health Centre of British Columbia, Vancouver
Registry updated 2026-10-07
NCT03816345
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Trial Treatment · Phase 1 · National Cancer Institute (NCI)
University Health Network, Princess Margaret Hospital, Toronto
Registry updated 2026-10-05
NCT06548399
Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease
Research · McMaster University
McMaster University, Hamilton
Registry updated 2026-10-01
NCT07013578
TIDHI Mental Health in IBD Patients Study
Trial Treatment · TIDHI Innovation Inc.
Toronto Immune and Digestive Health Institute, North YORK
Registry updated 2026-09-29

All Crohn's disease trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error